NGS amplification panel for HBV (Hepadnaviridae: <i>Orthohepadnavirus</i>) sequencing

Abstract

Introduction. Hepatitis B virus (HBV) remains a pressing global public health concern. The clinical course of the disease, particularly its tendency towards chronicity and response to therapy, is significantly influenced by the HBV genotype and specific mutations. There is an imperative need for a straightforward, highly sensitive, and dependable method for whole genome sequencing of HBV. Objective. Development and testing of an amplification panel for HBV whole-genome sequencing. Materials and methods. We introduce an NGS amplification panel designed for genome sequencing of HBV on the Illumina platform. A panel consisting of 54 primers, divided into 2 pools and amplifying overlapping regions of the HBV genome up to 300 bp in length, was tested on 246 HBV DNA samples. Results. The studied samples represented a genotypic diversity of the virus, with a pronounced predominance of the genotype specific to the Moscow region: 216, 27, 2, and 1 sample were identified as genotype D, A, B, and E, respectively. Five samples contained at least one mutation associated with antiviral therapy resistance, and twenty-three samples contained at least one mutation associated with vaccine escape described in the literature. Conclusion. The present paper describes the stages of whole-genome sequencing of HBV, provides a laboratory protocol, nucleotide sequences of the primers and an approach to the data analysis. Using a list of clinical samples as example, the reliability of the panel is shown. The HBV panel holds immense potential for utilization in scientific research, epidemiological monitoring, and advancement of personalized medicine approaches.